Iclaprim

Iclaprim
Clinical data
Routes of
administration		 Oral, intravenous
ATC code J01EA03 (WHO)
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Bioavailability Good (oral)[1]
Identifiers
CAS Number 192314-93-5 YesY
PubChem (CID) 213043
ChemSpider 184736 N
UNII 42445HUU0O N
KEGG D08337 YesY
ChEBI CHEBI:131724 N
ChEMBL CHEMBL134561 N
ECHA InfoCard 100.130.860
Chemical and physical data
Formula C19H22N4O3
Molar mass 354.403 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Iclaprim (INN), codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting extended-spectrum antibiotic active against gram positive organisms being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria.[2] It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant Staphylococcus aureus (MRSA).[3][4] In vitro, iclaprim is highly active against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria.[1]

A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008,[3] and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia.[4][5]

Iclaprim was granted fast track status by the FDA,[6] but approval of the drug was eventually declined in 2009[7] and no further development has taken place since then.

In Jan 2015, Motif BioSciences gained rights to iclaprim and planned to continue its development.[8] In 2016 phase 3 trials began.

Iclaprim & NADPH bound to DHFR. PDB entry: 3FRA. The different amino acids are color coded.

References

  1. 1 2 Kohlhoff SA, Sharma R (September 2007). "Iclaprim". Expert Opin Investig Drugs. 16 (9): 1441–8. doi:10.1517/13543784.16.9.1441. PMID 17714029.
  2. ↑ Kohlhoff, SA; Sharma, R (September 2007). "Iclaprim.". Expert Opinion on Investigational Drugs. 16 (9): 1441–8. doi:10.1517/13543784.16.9.1441. PMID 17714029.
  3. 1 2 "Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections" (Press release). Reuters. March 19, 2008. Retrieved 2008-08-24.
  4. 1 2 "Arpida's iclaprim MAA Accepted for Review by EMEA" (Press release). PR Newswire. August 21, 2008. Retrieved 2008-08-24.
  5. ↑ Peppard, WJ; Schuenke, CD (February 2008). "Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections". Current Opinion on Investigational Drugs. 9 (2): 210–25. PMID 18246524.
  6. ↑ Morgan A, Cofer C, Stevens DL (March 2009). "Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections". Future Microbiol. 4 (2): 131–44. doi:10.2217/17460913.4.2.131. PMID 19257839.
  7. ↑ Arpida receives FDA complete response letter for Iclaprim
  8. ↑ "Motif Bio Acquires Late Stage Antibiotic and Announces Pre-IPO Financing". Retrieved 2015-09-04.

Further reading

This article is issued from Wikipedia - version of the 10/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.